Neuromyelitis optica complicating COVID vaccinationsComment Published on 2022-06-012023-07-08 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), [키워드] COVID-19 safety profile SARS-CoV-2 Side effects vaccination [DOI] 10.1016/j.msard.2022.103809 PMC 바로가기 [Article Type] Comment
Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan대만의 건강한 성인에서 동종 및 이종 ChAdOx1-S 및 mRNA-1273 백신 접종의 면역원성과 안전성Article Published on 2022-06-012022-09-12 Journal: Journal of Clinical Virology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Abbott Diagnostics age antibody production Antibody Response Antibody titer booster doses ChAdOx1-S collected COVID-19 COVID-19 vaccine COVID-19 vaccines cPass™ detection division Elecsys® Anti-SARS-CoV-2 S Genscript Germany healthy Heterologous heterologous prime-boost homologous Homologous and heterologous prime-boost regimens homologous or heterologous humoral immune response IgG immunogenicity induce Ireland Moderna mRNA-1273 Neutralizing New Participants priming regimen robust Roche Diagnostics Safe Safety safety profile SARS-CoV-2 SARS-CoV-2 IgG serum sample shown Sligo Taiwan USA vaccination Vaccine were given were measured [DOI] 10.1016/j.jcv.2022.105156 PMC 바로가기 [Article Type] Article
Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot studyClinical Trial Published on 2022-05-262022-10-04 Journal: Stem Cell Research & Therapy [Category] 임상, [키워드] adipose administration adverse event adverse events assigned chest imaging Clinical characteristics clinical study COVID-19 COVID-19 patient COVID-19 patients D-dimer daily dose demographic data dose Efficacy Efficiency enrolled event Evidence Exosome Exosomes Extracellular vesicles feasible females Hospital admission IL-6 incidence inhalation interquartile range IQR laboratory result Lymphocyte count male median median age median time Mesenchymal stromal cell. MSC nebulized onset of symptom Patient patients patients with COVID-19 pilot study Pneumonia Primary outcome pulmonary lesion receive safety profile Serious Adverse Events serum Seven severe COVID-19 single-arm slight increase stromal cell supported tested tissue Toxicity Treatment Trial Vesicle vesicles Wuhan, China [DOI] 10.1186/s13287-022-02900-5 PMC 바로가기 [Article Type] Clinical Trial
A Multicenter Cohort Study on the Adverse Effects Evaluation After Messenger RNA COVID-19 Vaccination Among Pregnant Healthcare Employees in Penang General Hospitals페낭 종합병원 임산부의 코로나19 메신저 RNA 예방접종 후 부작용 평가에 대한 다기관 코호트 연구Multicenter Study Published on 2022-05-232022-09-11 Journal: Frontiers in Public Health [Category] COVID19(2023년), SARS, 치료기술, [키워드] accelerated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse adverse effect adverse effects post vaccination age anomalies Anomaly APGAR score appear approval Birth weight conducted coronavirus COVID-19 COVID-19 vaccine drug Drug administration Effect employee first vaccination followed by food gestational age growth hospital Inference intrauterine growth restriction Malaysia messenger mother mRNA mRNA vaccine MVP Neonatal Neonatal outcomes Neonate participant Penang Pregnancy pregnancy outcome pregnant pregnant women public health Regulatory reported retrospective cohort study RNA Safe safety of mRNA vaccine. safety profile SARS-CoV-2 second trimester Seven Spread subject the disease the mean trimester US Food and Drug Administration Vaccine Vaccine development widespread [DOI] 10.3389/fpubh.2022.876966 PMC 바로가기 [Article Type] Multicenter Study
Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in miceClofoctol은 SARS-CoV-2 복제를 억제하고 쥐의 폐 병리를 감소시킵니다Article Published on 2022-05-192022-09-11 Journal: PLoS Pathogens [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] antiviral activity Bacterial cells Clofoctol Compound compounds COVID-19 patients drug Drug repurposing exhibited exhibiting Gene Expression geographical areas human ACE2 receptor human lung IC50 identify Inflammatory inhibit investigated library Lung pathology mice peak concentration pharmacokinetic Pulmonary pathology reduce reduced Registered Regulatory Respiratory tract infections safety profile SARS-CoV-2 SARS-CoV-2 replication screened Support tested therapeutic Therapeutic treatment These data transgenic mice Treatment treatment of COVID-19 patients Viral load [DOI] 10.1371/journal.ppat.1010498 PMC 바로가기 [Article Type] Article
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants멀티토프 SARS-CoV-2 백신은 Delta 및 Omicron 변이체에 대해 오래 지속되는 B 세포 및 T 세포 면역을 제공합니다Clinical Trial Published on 2022-05-162022-09-11 Journal: The Journal of Clinical Investigation [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료법, [키워드] adverse event Antibody titers Asia B cell booster Breakthrough infection breakthrough infections center conducted conserved Control COVID-19 cross-reactive cytotoxic T lymphocyte Delta disease control dose elicited epitope Epitopes evaluated fatigue healthy helper T cell Heterologous human convalescent sera Immunity immunization immunogenicity Inc. injection site pain long-lasting lymphocyte membrane memory immunity Mild Ministry of Health Neutralizing antibodies Neutralizing antibody titer neutralizing antibody titers Neutralizing titer nucleocapsid omicron Omicron variants peptide peptides Phase I placebo-controlled Protein provide Randomized representing responsible safety profile sarbecovirus SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants second dose Serious Adverse Event Serious Adverse Events subunit Subunit vaccine T cell Taiwan Trial trials Vaccine variant variants of SARS-CoV-2 virus-neutralizing antibody VOCs waning immunity Welfare were recorded [DOI] 10.1172/JCI157707 PMC 바로가기 [Article Type] Clinical Trial
Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial성인을 위한 SARS-CoV-2 비활성화 백신의 3회 용량 요법의 면역원성 및 안전성: 무작위, 이중 맹검, 위약 대조 2상 시험Clinical Trial Published on 2022-05-162022-09-12 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 3-dose regimen acute respiratory syndrome Adults Adverse AEs antibody Antibody Response Control coronavirus dose doses double-blind Effective vaccines elicited event geometric mean titer GMT GMTs immune response immunogenicity Immunoglobulin inactivated Inactivated vaccine Injection-site pain intensity Neutralizing Neutralizing antibodies Older pandemic percentage Phase 2 Placebo placebo-controlled trial predominant pseudovirus Randomized receive Receptor binding domain robust Safety safety profile SARS-CoV-2 SARS-CoV-2 inactivated vaccine second dose separated serious AE tested the vaccine vaccination Vaccine virus were recorded [DOI] 10.1093/infdis/jiab627 PMC 바로가기 [Article Type] Clinical Trial
Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial Research Published on 2022-05-162022-10-05 Journal: Nature Medicine [Category] 임상, [키워드] adverse event Analysis approach Arm ARMS effective Efficacy Electronic cigarette help less Nicotine replacement not significantly different offered Other outcome outcomes participant pre-specified sensitivity analysis Pregnancy pregnant pregnant women Primary outcome Randomized Randomized controlled trial risk Safety safety profile smoking therapy women [DOI] 10.1038/s41591-022-01808-0 [Article Type] Research
A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19Research article Published on 2022-05-122022-10-05 Journal: EClinicalMedicine [Category] 신약개발, 임상, [키워드] Action acute respiratory syndrome adaptive clinical testing consumer coronavirus disease-2019 Coronavirus-2 COVID COVID-19 COVID-19 disease current decrease doses double-blinded Effect Efficacy and safety Emergency Endpoint enrolled Estrogen European Commission evaluate Evidence finding FIVE funding hospitalized patients immunomodulator indications instrument Italian Italy lack mechanical ventilation Medicine Mild Ministry of Health mitigate moderate Moderate COVID-19 modulate multicenter Multicenter trial Nasopharyngeal swab Occurrence participant Patient pharmacological Phase 2 study Placebo placebo-controlled placebo-controlled trial Prevent Primary outcome progression proinflammatory cytokines proportion raloxifene Randomized receive Registered Replication reported Safety safety profile SARS-CoV-2 Selective estrogen receptor modulator (SERM) Serious Adverse Events Seven supplemental oxygen Supplemental oxygen therapy Support supported therapeutic option treat Treatment Trial undetectable viral shedding [DOI] 10.1016/j.eclinm.2022.101450 [Article Type] Research article
Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection단일 용량 복제 폭스바이러스 벡터 기반 RBD 백신은 SARS-CoV-2 감염에 대한 강력한 체액 및 T 세포 면역 반응을 유도합니다.Clinical Trial Published on 2022-05-042022-09-11 Journal: Molecular therapy : the journal of the American So [Category] COVID19(2023년), MERS, SARS, 변종, 비임상, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration animal models Antigen approach breath complementary coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 cynomolgus macaques Dose escalation Efficacy evaluate the effect Express humoral immune immune response immune responses immunogenicity induce long-lasting mice Neutralizing antibodies outbreak pandemic poxvirus protective immunity RBD Receptor binding domain Replication respiratory response robust Safe safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 neutralizing antibodies SARS-CoV-2 neutralizing antibody SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus single dose Single-dose Support T cell T cell responses temperature Vaccine vaccine candidate vaccine platform Vaccines vaccinia virus vector [DOI] 10.1016/j.ymthe.2021.10.008 PMC 바로가기 [Article Type] Clinical Trial